Endonovo Therapeutics Inc (ENDV)
0.0022
0.00 (0.00%)
USD |
OTCM |
May 06, 16:00
Endonovo Therapeutics Gross Profit Margin (Quarterly): 49.57% for Dec. 31, 2023
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| December 31, 2023 | 49.57% |
| September 30, 2023 | 45.59% |
| June 30, 2023 | |
| March 31, 2023 | 95.44% |
| December 31, 2022 | 95.99% |
| September 30, 2022 | 63.26% |
| June 30, 2022 | 41.08% |
| March 31, 2022 | 68.71% |
| December 31, 2021 | -2.70K% |
| September 30, 2021 | 60.17% |
| June 30, 2021 | 98.35% |
| March 31, 2021 | 92.74% |
| December 31, 2020 | -309.1% |
| September 30, 2020 | 98.10% |
| June 30, 2020 | 74.68% |
| March 31, 2020 | 91.02% |
| December 31, 2019 | 68.22% |
| September 30, 2019 | 83.48% |
| June 30, 2019 | 52.86% |
| March 31, 2019 | 82.85% |
| December 31, 2018 | 80.85% |
| Date | Value |
|---|---|
| September 30, 2018 | 79.76% |
| June 30, 2018 | 95.72% |
| March 31, 2018 | |
| December 31, 2017 | |
| September 30, 2017 | |
| June 30, 2017 | |
| March 31, 2017 | |
| December 31, 2016 | |
| September 30, 2016 | |
| June 30, 2016 | |
| March 31, 2016 | |
| December 31, 2015 | |
| September 30, 2015 | |
| June 30, 2015 | 30.31% |
| March 31, 2015 | 69.98% |
| December 31, 2014 | 52.01% |
| September 30, 2014 | 23.32% |
| June 30, 2014 | 64.01% |
| March 31, 2014 | 52.43% |
| December 31, 2013 | 38.88% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
-2.70K%
Minimum
Dec 2021
98.35%
Maximum
Jun 2021
-101.9%
Average
68.47%
Median
Gross Profit Margin (Quarterly) Benchmarks
| NovaBay Pharmaceuticals Inc | 48.70% |
| Palatin Technologies Inc | 95.20% |
| iBio Inc | -- |
| Theriva Biologics Inc | -- |
| Oragenics Inc | -- |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Assets | 699.6% |
| Profit Margin (Quarterly) | -26.80K% |
| Operating Margin (Quarterly) | -13.14K% |